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Circulating Tumor DNA to Monitor Metastatic Breast Cancer
To the Editor: Dawson et al. (March 28 issue)1
suggest that the detection of circulating tumor
DNA in 58% of patients with metastatic breast
cancer can be used as an effective indicator of
tumor load during treatment with standard systemic therapies. The study does not address the
clinical utility of circulating tumor DNA. Moreover, the authors claim that circulating tumor
DNA represents a more effective monitoring tool
than the enumeration of circulating tumor cells.
This statement is incorrect, considering that the
enumeration of circulating tumor cells proved
the ability to predict prognosis and monitor
treatment efficacy in all patients with metastatic
breast cancer, regardless of disease subtype.2
Furthermore, new detection methods describe
the molecular heterogeneity and measure dynamic phenotypic changes in circulating tumor
cells during metastasis.3,4 We propose that circulating tumor DNA provides a complementary
method in the assessment of patients with detectable mutations and should be more appropriately used to select and monitor molecularly targeted therapies. Combined diagnostic methods
will provide a more effective approach than each
method alone to the implementation of precision
medicine and improved clinical outcomes.
Massimo Cristofanilli, M.D.
Paolo Fortina, Ph.D.
Kimmel Cancer Center
Philadelphia, PA
massimo.cristofanilli@jefferson.edu
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To the Editor: Dawson et al. propose circulating tumor DNA as a new biomarker for metastatic breast cancer. In our opinion, the timing of
the analysis is crucial for the correct interpretation of such data obtained from samples acquired
during chemotherapy.
Apoptosis leads to the augmented release of
cell-free DNA,1 so chemotherapy is expected to
temporarily increase the levels of circulating
tumor DNA. Thus, the assumption that such
increases reflect tumor load may be incorrect,
depending on the time point chosen.
We suggest a dual role for analysis with circulating tumor DNA. First, the difference between basal levels before and peak levels after
the administration of chemotherapy may serve
as an indicator of tumor responsiveness. Second,
levels of circulating tumor DNA measured several days after the last chemotherapy cycle may
serve as a surrogate marker for total tumor mass.
Analysis of the kinetics of circulating tumor
DNA during the use of various chemotherapeutic
drugs and regimens may pave the way for the
clinical translation of analysis with circulating
tumor DNA.
Lukas Weiss, M.D., Ph.D.
Clemens Hufnagl, M.Sc.
Richard Greil, M.D.
Paracelsus Medical University
Salzburg, Austria
r.greil@salk.at
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The Authors Reply: We support the idea that
combined methods involving circulating tumor
cells and circulating tumor DNA could be used to
analyze tumor status and changes. By the criterion of sensitivity for detection of disease burden, our data clearly show an advantage to the
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The timing of blood and plasma collection is
obviously an important variable. In our study, all
samples were collected immediately before the
administration of each treatment cycle. The possibility of measuring an increase in the release
of circulating tumor DNA as an indicator of responsiveness is attractive and is supported by
xenograft models.1

detection of circulating tumor DNA over the
enumeration of circulating tumor cells by
means of the CellSearch System. Our findings
provide the rationale for future studies to address the full clinical utility of analyses with
circulating tumor DNA.
One apparent limitation of our work was that
only two genes (PIK3CA and TP53) were analyzed
for most patients. These are the two most commonly mutated genes in breast cancer, and as
expected, they were informative in half the patients recruited. This does not represent a general limitation of circulating tumor DNA: as a
proof of principle, we also found that we were
able to monitor other somatic mutations and
structural variants in a subset of patients who
did not have mutations in PIK3CA or TP53. Our
data indicate that any cancer-specific mutation
can be monitored in circulating tumor DNA
from patients with metastatic breast cancer.

Sarah-Jane Dawson, Ph.D.
Nitzan Rosenfeld, Ph.D.
Carlos Caldas, M.D.
Cancer Research UK Cambridge Institute
Cambridge, United Kingdom
carlos.caldas@cruk.cam.ac.uk
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Globalization, Climate Change, and Human Health
To the Editor: The scholarly review of globalization and climate change by McMichael (April
4 issue)1 emphasizes the associated economic,
social, demographic, and environmental threats
to human health and suggests steps to mitigate
these changes on a global scale. Although McMichael also mentions the effects of climate change
and globalization on the geographic range of
vectorborne infections, he does not alert readers

to sobering examples of the emergence of tropical infections in the temperate zone (Table 1).
Globalization and climate change promote the
emergence of these infections synergistically.
Globalization increases the number of infected
travelers and the accidental importation of infected vectors. Climate change warms the environment to temperatures that permit reproduction of the vector and parasite. Increasing

Table 1. Effects of Globalization and Climate Change on the Spread of Tropical Infections to the Temperate Zone.*
Tropical
Infection

Areas of Local Transmission

Dengue

Key West and elsewhere in Florida;
Brownsville, Texas; France; and
Croatia and other areas of
southern Europe

Malaria

Greece

Chikungunya

Italy and France

Comment
A total of 5% of Key West residents
have antibodies against dengue,
and locally transmitted infections
have been reported in other
counties, including Miami–Dade;
39% of residents in Brownsville
have antibodies against dengue

Reference
Jordan et al.,2
Ramos et al.,3
Butler4

The CDC recommends precautions
(level 1) for persons who travel to
Greece, including consideration of
drug prophylaxis for travel to some
regions

CDC5

Hundreds of persons have been
infected in Italy

Butler4

* CDC denotes Centers for Disease Control and Prevention.
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